Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 106Neoplasm Metastasis 9Ovarian Neoplasms 3Carcinoma, Intraductal, Noninfiltrating 3Breast Neoplasms, Male 3Prostatic Neoplasms 2Obesity 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Breast Carcinoma In Situ 2Breast Cancer Metastatic 2Arthralgia 2Triple Negative Breast Neoplasms 1Sexuality 1Sexual Dysfunctions, Psychological 1Recurrence 1Primary Breast Cancer ER+ve 1Premenopausal Breast Cancer 1Patient Acceptance of Health Care 1Pancreatic Neoplasms 1Pain 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Multiple Endocrine Neoplasia Type 1 1Metastatic Beast Cancer 1Locoregional Recurrence 1Hyperglycemia 1Human Epidermal Growth Factor 2 Negative Carcinoma of Breast 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Hormone Receptor Positive Malignant Neoplasm of Breast 1HR Positive HER2 Negative Advanced Breast Cancer 1

Interventions

Letrozole 2exemestane 1dalpiciclib 1Tamoxifen 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HR Positive HER2 Negative Advanced Breast Cancer × exemestane × Clear all
NCT05890287 2023-06-06

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
60 enrolled
Breast

HR Positive HER2 Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡